Rigshospitalet, Denmark
rigshospitalet.dkLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,038
Active
205
Phase 3
43
Total enrollment
1,928,041
Pipeline matrix
Showing 40 of 79 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fluconazole | — | — | — | — | — | 2 | |
| Escitalopram | — | — | — | — | 2 | ||
| Semaglutide 14 MG [Rybelsus] | — | — | — | — | — | 1 | |
| Pivmecillinam | — | — | — | — | — | 1 | |
| Amoxicillin clavulanic acid | — | — | — | — | — | 1 | |
| Amoxicillin | — | — | — | — | — | 1 | |
| Cefuroxime | — | — | — | — | — | 1 | |
| Ciprofloxacin | — | — | — | — | — | 1 | |
| Linezolid | — | — | — | — | — | 1 | |
| Nitrofurantoin | — | — | — | — | — | 1 | |
| Trimethoprim | — | — | — | — | — | 1 | |
| Sulfamethoxazole trimethoprim | — | — | — | — | — | 1 | |
| S-ketamine | — | — | — | — | — | 1 | |
| Discontinuation of 2nd generation combined oral contraceptive use | — | — | — | — | — | 1 | |
| Continuation of 2nd generation combined oral contraceptive use | — | — | — | — | — | 1 | |
| Targeted serum potassium level | — | — | — | — | — | 1 | |
| Xalatan | — | — | — | — | — | 1 | |
| Monoprost | — | — | — | — | — | 1 | |
| Furosemide | — | — | — | — | — | 1 | |
| Isosorbide Dinitrate | — | — | — | — | — | 1 | |
| Furosemide and isosorbide dinitrate | — | — | — | — | — | 1 | |
| Adjunctive anemia therapy | — | — | — | — | — | 1 | |
| Isotonic saline solution | — | — | — | — | — | 1 | |
| dupilumab | — | — | — | — | — | 1 | |
| mepolizumab | — | — | — | — | — | 1 | |
| DUPIXENT® | — | — | — | — | — | 1 | |
| NUCALA® | — | — | — | — | — | 1 | |
| increased dosing interval of biological therapy | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | 2 | ||
| Methylprednisolone | — | — | — | 9 | |||
| Dexamethasone | — | — | — | — | 8 | ||
| Paracetamol | — | — | — | — | 3 | ||
| Melatonin | — | — | — | — | — | 1 | |
| Isotonic sodium chloride solution | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Ocrelizumab | — | — | — | — | — | 1 | |
| Fexofenadine | — | — | — | — | — | 1 | |
| Alteplase 20 Mg Powder for Solution for Injection Vial | — | — | — | — | — | 1 | |
| Azithromycin 40 MG/ML | — | — | — | — | — | 1 | |
| Acalabrutinib | — | — | — | — | — | 1 |
39 more active programs hidden
Next readouts
- 2024-06-05
- 2024-09
- 2025-04-01
- 2025-05-09
- 2025-06-30
- 2025-12
- 2025-12
- 2026-04-01
- 2026-04-01
- 2026-06-10
Top conditions
- Breast Cancer17
- Healthy17
- Pain15
- Cancer15
- Coronary Artery Disease13
- Surgery13
- Type 2 Diabetes12
- Cardiovascular Diseases11
Frequently asked questions about Rigshospitalet, Denmark
- How many clinical trials does Rigshospitalet, Denmark have on ClinicalTrials.gov?
- Rigshospitalet, Denmark is listed as the lead sponsor on 1,038 clinical trials in ClinicalTrials.gov, 205 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Rigshospitalet, Denmark's trials are in Phase 3?
- 43 of Rigshospitalet, Denmark's trials are in Phase 3, spread across 79 active drug programs.
- What therapeutic areas does Rigshospitalet, Denmark focus on?
- Rigshospitalet, Denmark's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Healthy, Pain, Cancer, Coronary Artery Disease.
- When are Rigshospitalet, Denmark's next clinical trial readouts?
- Rigshospitalet, Denmark has 10 upcoming primary-completion readouts tracked here; the soonest is “Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism”, expected around 2024-06-05.